Furthermore, this gene-enhanced nuclear-targeting SDT strategy can induce ICD to improve the immunosuppressive microenvironment, thus boosting DPPA-1 peptide-based anti-PD-L1 therapy of CRC and inhibiting its intestinal metastasis through activation of the systemic immune response. Here, CD274 is linked to colorectal carcinoma.